{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T07:05:24Z","timestamp":1778137524704,"version":"3.51.4"},"reference-count":12,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,4]]},"DOI":"10.1097\/meg.0000000000000045","type":"journal-article","created":{"date-parts":[[2014,1,24]],"date-time":"2014-01-24T09:33:21Z","timestamp":1390556001000},"page":"458-465","source":"Crossref","is-referenced-by-count":37,"title":["Mucosal healing in pediatric Crohn\u2019s disease after anti-TNF therapy"],"prefix":"10.1097","volume":"26","author":[{"given":"Stefano","family":"Nobile","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo","family":"Gionchetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fernando","family":"Rizzello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlo","family":"Calabrese","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Massimo","family":"Campieri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R10-13-20210207","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.crohns.2011.02.007","article-title":"Adalimumab as second line anti-tumour necrosis factor alpha therapy for Crohns disease: a single centre experience.","volume":"5","author":"Sprakes","year":"2011","journal-title":"J Crohns Colitis"},{"key":"R12-13-20210207","doi-asserted-by":"crossref","first-page":"3814","DOI":"10.3748\/wjg.15.3814","article-title":"Adalimumab in ulcerative colitis: two cases of mucosal healing and clinical response at two years.","volume":"15","author":"Barreiro-de Acosta","year":"2009","journal-title":"World J Gastroenterol"},{"key":"R22-13-20210207","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1002\/ibd.20069","article-title":"Linear growth improves during infliximab therapy in children with chronically active severe Crohns disease.","volume":"13","author":"Walters","year":"2007","journal-title":"Inflamm Bowel Dis"},{"key":"R26-13-20210207","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1007\/s10620-009-0791-7","article-title":"Adalimumab treatment in children with refractory Crohns disease.","volume":"55","author":"Rosenbach","year":"2010","journal-title":"Dig Dis Sci"},{"key":"R28-13-20210207","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/MPG.0b013e318174e886","article-title":"Safety and efficacy of adalimumab in pediatric patients with Crohn disease.","volume":"47","author":"Wyneski","year":"2008","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"R29-13-20210207","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1002\/ibd.20534","article-title":"Short-term response to adalimumab in childhood inflammatory bowel disease.","volume":"14","author":"Noe","year":"2008","journal-title":"Inflamm Bowel Dis"},{"key":"R31-13-20210207","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1097\/MPG.0b013e3181a712db","article-title":"Oropharyngeal and proximal esophageal involvement during adalimumab treatment of Crohn disease.","volume":"50","author":"Nguyen","year":"2010","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"R32-13-20210207","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1097\/01.mpg.0000169275.86308.b0","article-title":"Adalimumab, a novel anti-tumor necrosis factor-alpha antibody in a child with refractory Crohns disease.","volume":"41","author":"Mian","year":"2005","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"R33-13-20210207","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1097\/MPG.0b013e318124504b","article-title":"Adalimumab induces and maintains remission in severe, resistant paediatric Crohn disease.","volume":"46","author":"Hadziselimovic","year":"2008","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"R34-13-20210207","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.crohns.2010.04.002","article-title":"Long-term efficacy of adalimumab in paediatric Crohns disease patients naive to other anti-TNF therapies.","volume":"4","author":"Martin-de-Carpi","year":"2010","journal-title":"J Crohns Colitis"},{"key":"R35-13-20210207","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1097\/00054725-200407000-00024","article-title":"Mucosal healing in pediatric Crohns disease: the goal of medical treatment.","volume":"10","author":"DHaens","year":"2004","journal-title":"Inflamm Bowel Dis"},{"key":"R40-13-20210207","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1053\/gast.2003.50145","article-title":"Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohns disease: a randomized controlled trial.","volume":"124","author":"Farrell","year":"2003","journal-title":"Gastroenterology"}],"container-title":["European Journal of Gastroenterology & Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MEG.0000000000000045","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T03:48:07Z","timestamp":1620964087000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00042737-201404000-00013"}},"subtitle":["a long-term experience at a single center"],"short-title":[],"issued":{"date-parts":[[2014,4]]},"references-count":12,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.1097\/meg.0000000000000045","relation":{},"ISSN":["0954-691X"],"issn-type":[{"value":"0954-691X","type":"print"}],"subject":[],"published":{"date-parts":[[2014,4]]}}}